Zhongzheng Intelligent Finance News Hualan Vaccine (301207) announced on the evening of August 13 that it has recently received the "Notice of Approval for Drug Clinical Trials" issued by the National Medical Products Administration for its freeze-dried Haemophilus influenzae type b conjugate vaccine (Hib vaccine). Agree to conduct clinical trials of this vaccine for the prevention of invasive infections caused by Haemophilus influenzae type b, including meningitis, pneumonia, sepsis, etc.

It is reported that approximately 95% of invasive diseases caused by Haemophilus influenzae are triggered by type b strains. The Hib vaccine developed by the company is composed of purified Hib capsular polysaccharides combined with tetanus toxoid protein, and is in a freeze-dried dosage form. After vaccination, it can induce an immune response against Hib to provide protection. In addition, this vaccine is a component of the combined vaccine based on the component DPT that the company is developing. The approval of the single vaccine for clinical trials this time will lay the foundation for accumulating clinical data and promoting the registration and application of the combined vaccine.

The company stated that the approval of the "Freeze-dried Hib vaccine" is a phased success in the company's product research and development strategic layout. It not only enriches the company's product layout but also is an important step towards achieving the company's research and development of multi-component and multi-valent products. It is conducive to consolidating the company's industry position in the domestic second-class vaccine field and the sustainable development of the company's vaccine business.